We are one of the leading generic pharmaceutical companies in Central Eastern Europe, and our activities incorporate all areas of the pharmaceutical value chain. Egis is a member of the Servier Group, an international pharmaceutical company governed by a non-profit foundation with its headquarters in France.
In the 2019/2020 financial year, Egis Group generated net sales of EUR 542 million. Besides Hungary, we sell our products under Egis’ brand names in 17 countries through our network of subsidiaries and representative offices.
Our products range from active ingredients, through tablets and injections, to galenic (i.e. liquid and semi-solid) formulations and are available in 60 countries in total through our network of subsidiaries and representative offices or partners. Last financial year our portfolio consisted of 617 products that belonged to 161 product lines and contained 146 active ingredients.
Our focus lies on treating diseases of the cardiovascular and central nervous systems; however, we also provide modern treatment solutions in the fields of oncology and women’s health. In 2013, we launched our first biosimilar monoclonal antibody product. This was also the first biosimilar monoclonal antibody (mAb) in the European Union. Since then we launched three additional biosimilar drugs.
As one of the companies in the Central Eastern European region firmly committed to innovation, we devote about 50 EUR million yearly to R&D. Our research and development activities focus on high-quality, value-added branded generic products.
In the last twenty years, we have invested more than EUR 740 million in improvements — such as modernizing the complete process of our finished product manufacturing, as well as establishing state-of-the-art R&D centers in Hungary. Development of highly potent (meaning having significant biological activity in very small doses) drug substances and finished products has also become possible at our site in Budapest, where the comprehensive modernization of the traditional technology of active ingredient manufacturing has also been completed. Currently, some large-scale development activities are being carried out, such as the extension of one of our existing packaging plants, and the establishment of the capacity to cover the whole manufacturing value chain of highly potent medicines. We also inaugurated a new galenic plant in September 2019.
data not audited